Kymera Perspectives
Hear from our team on recent breakthroughs, scientific and clinical advancements, company culture, and our ongoing work to develop new medicines at Kymera.
A New Era of Possibility: Addressing Coveted Undrugged Targets
With our unique approach and deep drug discovery expertise, we are advancing a pipeline of oral small molecule degrader programs addressing high value targets in key immuno-inflammatory signaling pathways to create unprecedented possibilities for patients. Hear from Juliet Williams, PhD, Head of Research, on how our team’s commitment to innovation and first-in-class science will position us well on our mission to build a global medicines company that revolutionizes the treatment of immunological diseases.
Featured
Stay ahead with the latest news from Kymera. Our Press Releases provide insights into our recent achievements and future endeavors.
Related Stories
